AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, and durability NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago.

PRNewsWire • May 5, 2026

Inspire Investing Announces Lower Expense Ratios on 5 Faith-Based ETFs

BOISE, Idaho, April 28, 2026 /PRNewswire/ -- Inspire Investing, the world's largest provider of Christian ETFs, reported expense ratio reductions on five of its exchange traded funds. These reductions range from 2.7% to 7.6% for an overall average decrease of 5.3%.

PRNewsWire • Apr 28, 2026

Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?

Designed to provide broad exposure to the Investment Grade Corporate Bond ETFs category of the market, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund launched on 07/10/2017.

Zacks Investment Research • Apr 7, 2026

Hyper Scale: AI's Massive Financing Needs In Focus

AI development requires large projects to establish computing power. That in turn requires massive amounts of financing.

Seeking Alpha • Dec 19, 2025

What's Going On With Treasury Rates?

We think the Fed has time to assess the impact of tariffs, and we expect it to wait to cut rates until the data show that tariffs are impacting the real economy. So far, there are no signs of recession in the hard data. The tariff pause offers the possibility to avoid worst-case economic scenarios before the damage is crystalized. We believe technical factors will continue to drive market dislocations in spreads and sectors, and that active managers can navigate this more effectively.

Seeking Alpha • Apr 18, 2025

Scripps Research Advances Breakthrough Regenerative Medicines to Reverse Aging-Related Diseases

LA JOLLA, Calif.--(BUSINESS WIRE)--As people live longer than ever before, the incidence of aging-related, chronic diseases is on the rise, severely impacting quality of life and placing an unprecedented financial and care burden on overwhelmed families, government agencies and healthcare providers. To help address this growing challenge, scientists at Scripps Research and its nonprofit drug development arm, the Calibr-Skaggs Institute for Innovative Medicines, are advancing novel regenerative.

Business Wire • Oct 30, 2024

Funds Keep Loading Up On Nvidia, Meta And Three Other Magnificent Seven Stocks

Nvidia stock is one of 15 stocks funds are buying even as markets come under pressure. Other stocks include Meta, Google, Amazon and Microsoft.

Investors Business Daily • Apr 17, 2024

The Credit Opportunity In M&A

M&A was almost dormant in 2023. In the US, as a proportion of the market value of the benchmark equity indices, it fell to its lowest level in 20 years, according to McKinsey. Credit investors are not traditionally supposed to be fans of M&A, and it's true we are wary of leveraging M&A, where debt is loaded onto balance sheets to buy competitors. We are seeing a comeback for M&A that we think is likely to continue through 2024.

Seeking Alpha • Mar 4, 2024

11 Stocks Are Primed To Blow Away Earnings Expectations

Want to put an S&P 500 investor in a good mood during earnings season? A huge earnings surprise would do it.

Investors Business Daily • Oct 14, 2022

Is Inspire Corporate Bond ESG ETF (IBD) a Strong ETF Right Now?

Smart Beta ETF report for IBD

Zacks Investment Research • Jul 13, 2022